Join the Oncology Voice Network. Join for Free
Effective Relationship Strategies for MSL Success with Commercial Counterparts
MSL-to-sales rep ratio Medical Science Liaisons effective communication strategies compliance challenges successful commercial relationships

Effective Relationship Strategies for MSL Success with Commercial Counterparts


Share This Article


Summary

In this episode, Tom Caravela hosts Rob Rosti to delve into the critical dynamics between Medical Science Liaisons (MSLs) and commercial teams. Rob shares his background and highlights the significance of maintaining a balanced MSL-to-sales rep ratio. The discussion navigates the distinct roles and expectations of MSLs versus sales reps, emphasizing effective communication strategies. The episode addresses potential issues, compliance challenges, and strategies for handling non-compliance requests. Rob offers advice for new MSLs, focusing on fostering successful commercial relationships. The episode wraps up with final thoughts and a call to action for listeners.

My guest today is Robert Rosti, Senior Medical Science Liaison with TerSera Therapeutics and we discuss Effective Relationship Strategies for MSL Success with Commercial Counterparts

Rob shares…

👉 Typical MSL support expectations for sales reps and Managers
👉 Rules of the Road for MSLs vs Commercial
👉 Best practices for MSLs in communicating with sales counterparts
👉 What issues and pitfalls MSLs should look out for
👉 Advice for MSLs to ensure successful relationships with sales colleagues

Click for Source
MSL-to-sales rep ratio, Medical Science Liaisons, effective communication strategies, compliance challenges, successful commercial relationships

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
How to Start Presenting Like a Pro
Partner Avatar MSL Talk: Tom Caravela

How to Start Presenting Like a Pro

Podcast
MSL Career Options: The transition from Field Medical to Medical Director
Partner Avatar MSL Talk: Tom Caravela, Josh Corriveau

MSL Career Options: The transition from Field Medical to Medical Director

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Explore OVN